Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other Non-Current Liabilities (2016 - 2025)

Conmed (CNMD) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $63.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 26.01% year-over-year to $63.9 million, compared with a TTM value of $63.9 million through Dec 2025, down 26.01%, and an annual FY2025 reading of $63.9 million, down 26.01% over the prior year.
  • Other Non-Current Liabilities was $63.9 million for Q4 2025 at Conmed, down from $71.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $218.1 million in Q3 2022 and bottomed at $41.8 million in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $103.6 million, with a median of $90.5 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities soared 373.8% in 2022, then plummeted 41.41% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $43.0 million in 2021, then skyrocketed by 373.8% to $203.7 million in 2022, then crashed by 40.58% to $121.0 million in 2023, then dropped by 28.7% to $86.3 million in 2024, then decreased by 26.01% to $63.9 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CNMD at $63.9 million in Q4 2025, $71.7 million in Q3 2025, and $79.8 million in Q2 2025.